The study is a double-blind, placebo-controlled study of BG00012 plus methotrexate, versus methotrexate alone, in patients with active RA, who have had an incomplete response to other conventional disease modifying anti-rheumatic (DMARD) therapy.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00810836?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
